SCHEMBL24654083

SCHEMBL24654083

CC(C)CCCNC(=O)C1(C)CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.44
DRD4 P21917 2/20 0.44
CETP P11597 4/20 0.42
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
CCR2 P41597 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
P2RX7 Q99572 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
DPP4 P27487 1/20 0.33
MAPK1 P28482 1/20 0.33
MMP2 P08253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25632161 0.98 DRD2 (0.42) DRD2DRD4CETPCYP3A4CYP2C19
SCHEMBL24654080 0.95 CYP3A4 (0.41) DRD2DRD4CETPCYP3A4CYP2C19
SCHEMBL29306394 0.91 CYP3A4 (0.43) DRD2DRD4CETPCYP3A4CYP2C19
SCHEMBL19199227 0.80 SMN1; SMN2 (0.42) CYP3A4CYP2C19SMN1; SMN2HPGDLMNA
SCHEMBL24654166 0.80 CYP3A4 (0.37) DRD2DRD4CETPCYP3A4CYP2C19
SCHEMBL29306660 0.79 SPHK1 (0.50) DRD2DRD4
SCHEMBL24654085 0.79 ACHE (0.46) DRD2DRD4CYP3A4CYP2C19SMN1; SMN2
SCHEMBL27886475 0.77 SMN1; SMN2 (0.47) DRD2DRD4CETPCYP3A4CYP2C19
SCHEMBL22170861 0.77 PAOX (0.50) DRD2DRD4CYP3A4CYP2C19SMN1; SMN2
SCHEMBL26717052 0.76 CYP3A4 (0.38) CETPCYP3A4CYP2C19SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed
WO-2022204288-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS PLTP, LNPK, PLIN3 DRD2 4796/4885DRD4 4749/4885CETP 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.